We have located links that may give you full text access.
Gentamicin Administration in Dialysis Patients: Before or After Hemodialysis?
Therapeutic Drug Monitoring 2022 October 27
BACKGROUND: Gentamicin is used to treat severe infections and has a small therapeutic window. This study aimed to optimize the dosing strategy of gentamicin in intermittently hemodialyzed patients by simulating concentration/time profiles during pre- and post-dialysis dosing, based on a published pharmacokinetic model.
METHODS: Pharmacokinetic simulations were performed with virtual patients, including septic patients, who were treated with gentamicin and received weekly hemodialysis with an interval of 48h-48h-72h. The following dosing regimens were simulated: for non-septic patients, 5 mg/kg gentamicin was given 1h/2h before dialysis, or a starting dose of 2.5 mg/kg and a maintenance dose of 1.5 mg/kg immediately after dialysis; for septic patients, 6 mg/kg gentamicin was given 1h/2h before dialysis, or a starting dose of 3 mg/kg and a maintenance dose of 1.8 mg/kg immediately after dialysis. The mean Cmax, AUC24h, and target attainment (TA) of pharmacodynamic targets were calculated and compared. The following targets were adopted from literature: Cmax >8 mg/L and <20 mg/L and AUC24h >70 mg·h/L and <120 mg·h/L.
RESULTS: In non-septic patients, postdialysis dosing resulted in a TA of 35% for Cmax >8 mg/L, 100% for <20 mg/L and AUC24h >70 mg·h/L, and 45% for <120 mg·h/L. Dosing 2h prior to dialysis resulted in a TA of 100% for Cmax> 8 mg/L, 40% for <20 mg/L, 65% for AUC24h >70 mg·h/L, and 77% for <120 mg·h/L. Simulations of septic patients resulted in comparable outcomes with higher TAs for Cmax <20 mg/L (96%), AUC24h >70 mg·h/L (90%), and <120 mg·h/L (53%) for dosing 1h prior to dialysis.
CONCLUSIONS: Postdialysis dosing resulted in a low TA of Cmax >8 mg/L; however, predialysis dosing ensured a high TA of Cmax >8 mg/L and acceptable TA of Cmax <20 mg/L, AUC24h >70 mg·h/L, and <120 mg·h/L, which could increase the efficacy of gentamicin. Therefore, clinicians should consider predialysis dosing of gentamicin in patients undergoing intermittent hemodialysis.
METHODS: Pharmacokinetic simulations were performed with virtual patients, including septic patients, who were treated with gentamicin and received weekly hemodialysis with an interval of 48h-48h-72h. The following dosing regimens were simulated: for non-septic patients, 5 mg/kg gentamicin was given 1h/2h before dialysis, or a starting dose of 2.5 mg/kg and a maintenance dose of 1.5 mg/kg immediately after dialysis; for septic patients, 6 mg/kg gentamicin was given 1h/2h before dialysis, or a starting dose of 3 mg/kg and a maintenance dose of 1.8 mg/kg immediately after dialysis. The mean Cmax, AUC24h, and target attainment (TA) of pharmacodynamic targets were calculated and compared. The following targets were adopted from literature: Cmax >8 mg/L and <20 mg/L and AUC24h >70 mg·h/L and <120 mg·h/L.
RESULTS: In non-septic patients, postdialysis dosing resulted in a TA of 35% for Cmax >8 mg/L, 100% for <20 mg/L and AUC24h >70 mg·h/L, and 45% for <120 mg·h/L. Dosing 2h prior to dialysis resulted in a TA of 100% for Cmax> 8 mg/L, 40% for <20 mg/L, 65% for AUC24h >70 mg·h/L, and 77% for <120 mg·h/L. Simulations of septic patients resulted in comparable outcomes with higher TAs for Cmax <20 mg/L (96%), AUC24h >70 mg·h/L (90%), and <120 mg·h/L (53%) for dosing 1h prior to dialysis.
CONCLUSIONS: Postdialysis dosing resulted in a low TA of Cmax >8 mg/L; however, predialysis dosing ensured a high TA of Cmax >8 mg/L and acceptable TA of Cmax <20 mg/L, AUC24h >70 mg·h/L, and <120 mg·h/L, which could increase the efficacy of gentamicin. Therefore, clinicians should consider predialysis dosing of gentamicin in patients undergoing intermittent hemodialysis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app